A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects

• Published in: PloS one Vol. 11; no. 6; p. e0157335
• Main Authors: Greenberg, Richard N., Hay, Christine M., Stapleton, Jack T., Marbury, Thomas C., Wagner, Eva, Kreitmeir, Eva, Röesch, Siegfried, von Krempelhuber, Alfred, Young, Philip, Nichols, Richard, Meyer, Thomas P., Schmidt, Darja, Weigl, Josef, Virgin, Garth, Arndtz-Wiedemann, Nathaly, Chaplin, Paul
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 21.06.2016; Public Library of Science (PLoS)
• Subjects: Aged, 80 and over; Analysis; Biology and Life Sciences; Body temperature; Clinical trials; Demography; Double-Blind Method; Double-blind studies; EKG; Enzyme-Linked Immunosorbent Assay; Erythema; Fatigue; Female; Headache; Health care; HIV; Human immunodeficiency virus; Humans; Immune response (humoral); Immune system; Immunogenicity; Immunological memory; Infections; Injection; Lymphocytes B; Male; Medical prognosis; Medicine and Health Sciences; Middle Aged; Myalgia; Nausea; Neutralization; Pain; Placebos; Population; Product development; Pruritus; Public health; Replicating; Replication; Research and Analysis Methods; Safety; Seroconversion; Smallpox; Smallpox Vaccine - adverse effects; Smallpox Vaccine - immunology; Smallpox vaccines; Studies; Vaccination; Vaccines; Vaccines, DNA; Vaccinia; Variola major; Viral Plaque Assay; Viral Vaccines - adverse effects; Viral Vaccines - immunology; Viruses; United States; Ankara Turkey; Iowa City Iowa; Turkey; United States > US; Germany

Modified Vaccinia Ankara MVA-BN® is a live, highly attenuated, viral vaccine under advanced development as a non-replicating smallpox vaccine. In this Phase II trial, the safety and immunogenicity of Modified Vaccinia Ankara MVA-BN® (MVA) was assessed in a 56-80 years old population. MVA with a viru...